Evidence map›Paper›PMID 29357123›Full record

ReviewComprehensive Physiology2017

Triglyceride Metabolism in the Liver.

Michele Alves-Bezerra, David E Cohen

Abstract readReview
In one paragraph

Review in Comprehensive Physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 659 papers.

0numbers the graph read from it
0cells of the map it votes in
659citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

659 citing papers in PubMed, 1,012 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Vanadium(IV)-chlorodipicolinate alleviates hepatic steatosis via the AMPK/PGC-1α/CPT1a axis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

599 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michele Alves-BezerraJoan & Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, USA.
David E CohenJoan & Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, USA.
Cornell University · US

Funding

Phospholipid-Mediated Metabolic Control in the Pathogenesis of NAFLDR01DK056626 · NIDDK · YESHIVA UNIVERSITY · PI COHEN, DAVID E. · 2000 to 2024
$10.3M
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLDR01DK103046 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI DAVID E. COHEN, Susan J Hagen · 2015 to 2026
$7.6M
Regulation of Hepatic Lipid and Glucose Metabolism by PC-TP/StarD2R37DK048873 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI COHEN, DAVID E. · 2012 to 2021
$5.5M
NIDDK NIH HHS R01 DK056626NIDDK NIH HHS R01 DK103046NIDDK NIH HHS R37 DK048873
6 · The paper itself

Abstract

Triglyceride molecules represent the major form of storage and transport of fatty acids within cells and in the plasma. The liver is the central organ for fatty acid metabolism. Fatty acids accrue in liver by hepatocellular uptake from the plasma and by de novo biosynthesis. Fatty acids are eliminated by oxidation within the cell or by secretion into the plasma within triglyceride-rich very low-density lipoproteins. Notwithstanding high fluxes through these pathways, under normal circumstances the liver stores only small amounts of fatty acids as triglycerides. In the setting of overnutrition and obesity, hepatic fatty acid metabolism is altered, commonly leading to the accumulation of triglycerides within hepatocytes, and to a clinical condition known as nonalcoholic fatty liver disease (NAFLD). In this review, we describe the current understanding of fatty acid and triglyceride metabolism in the liver and its regulation in health and disease, identifying potential directions for future research. Advances in understanding the molecular mechanisms underlying the hepatic fat accumulation are critical to the development of targeted therapies for NAFLD. © 2018 American Physiological Society. Compr Physiol 8:1-22, 2018.

Indexed as

Biological TransportFatty AcidsHumansLipid MetabolismLipogenesisLipolysisLiverNon-alcoholic Fatty Liver DiseaseTriglyceridesFatty AcidsTriglycerides

Identifiers

PMID29357123
PMCPMC6376873
OpenAlexW2788261792

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.